Lindsey Shapiro, PhD, science writer —

Investigational oral therapy IMM-1-104 was well tolerated and showed early signs of efficacy as a first- or second-line treatment for pancreatic cancer. That’s according…

Brainchild Bio plans to launch a pivotal Phase 2 clinical trial to test its investigational cell therapy BCB-276 in patients with diffuse intrinsic pontine…

The U.S. Food and Drug Administration (FDA) has agreed to review Verastem Oncology’s application seeking approval of a combination of avutometinib and defactinib for…

A protein called PRKAA1 could be among potential pancreatic cancer biomarkers and a possible treatment target, a study found. Levels of the protein were…

Researchers have uncovered genetic changes that may explain why certain brain tumors, known as gliomas, that are associated with IDH gene mutations start off as…

The first recorded case of vulvar cancer that occurred alongside an infection with the Fusobacterium necrophorum bacteria was described in a recent case report…

Doctors should consider the possibility of a pancreatic neuroendocrine tumor (pNET) when patients with a history of abdominal and back pain seek treatment. That’s…

Real-world treatment with the cell therapy Carvykti (ciltacabtagene autoleucel) was found to be highly effective among people with difficult-to-treat multiple myeloma in a multicenter…

A single infusion of the cell therapy Carvykti (ciltacabtagene autoleucel) reduced the risk of death by 45% relative to standard treatment regimens for multiple…

The U.S. Food and Drug Administration has approved Sanofi’s Sarclisa (isatuximab) in combination with standard-of-care treatment for adults with newly diagnosed multiple myeloma…